VÃ-ctor Vinuesa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5875245/publications.pdf Version: 2024-02-01

		257429	276858
130	2,625	24	41
papers	citations	h-index	g-index
131	131	131	4063
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. Journal of Medical Virology, 2022, 94, 491-498.	5.0	17
2	Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents. Clinical Microbiology and Infection, 2022, 28, 279-284.	6.0	17
3	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leukemia and Lymphoma, 2022, 63, 538-550.	1.3	8
4	Human genetic polymorphisms and risk of viral infection after solid organ transplantation Transplantation Reviews, 2022, 36, 100669.	2.9	7
5	Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine. Journal of Infection, 2022, 84, 418-467.	3.3	3
6	Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19. Journal of Infection, 2022, 84, 579-613.	3.3	5
7	Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances, 2022, 6, 848-853.	5.2	5
8	Monitoring of Torque Teno virus DNAemia in critically ill COVID-19 patients: May it help to predict clinical outcomes?. Journal of Clinical Virology, 2022, 148, 105082.	3.1	12
9	RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. Journal of Infection, 2022, 84, 579-613.	3.3	9
10	Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant. Journal of Infection, 2022, 84, e64-e66.	3.3	30
11	SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine. Journal of Infection, 2022, 84, 834-872.	3.3	2
12	Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination. CKJ: Clinical Kidney Journal, 2022, 15, 1562-1573.	2.9	15
13	Human pegivirus type 1 infection in kidney transplant recipients: Replication kinetics and clinical correlates. Transplant Infectious Disease, 2022, 24, .	1.7	3
14	Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2021, 93, 5167-5172.	5.0	8
15	Amplification of human βâ€glucuronidase gene for appraising the accuracy of negative SARS oVâ€2 RTâ€PCR results in upper respiratory tract specimens. Journal of Medical Virology, 2021, 93, 48-50.	5.0	11
16	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. American Journal of Transplantation, 2021, 21, 258-271.	4.7	11
17	Caveats in interpreting SARS oVâ€2 IgM ⁺ /IgG ^{â^'} antibody profile in asymptomatic health care workers. Journal of Medical Virology, 2021, 93, 634-636.	5.0	10
18	Qualitative assessment of SARSâ€CoVâ€2â€specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay. Journal of Medical Virology, 2021, 93, 1141-1144.	5.0	16

#	Article	IF	CITATIONS
19	Suitability of two rapid lateral flow immunochromatographic assays for predicting SARSâ€CoVâ€2 neutralizing activity of sera. Journal of Medical Virology, 2021, 93, 2301-2306.	5.0	12
20	Field evaluation of a rapid antigen test (Panbioâ,,¢ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clinical Microbiology and Infection, 2021, 27, 472.e7-472.e10.	6.0	245
21	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplantation, 2021, 56, 1281-1290.	2.4	3
22	Assessing the potential association between SARSâ€CoVâ€2 RNA load in the respiratory tract and COVIDâ€19 mortality. Journal of Medical Virology, 2021, 93, 1862-1864.	5.0	2
23	Fundamentos e implementación de Programas de Optimización de Diagnóstico Microbiológico. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 248-251.	0.5	4
24	Diagnostic significance of SARS-CoV-2 lgM positive/lgG negative antibody profile in symptomatic patients with suspected COVID-19 testing negative by RT-PCR. Journal of Infection, 2021, 82, e15-e16.	3.3	4
25	SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19 Transplantation, 2021, Publish Ahead of Print, 1372-1380.	1.0	17
26	Recent Advances in Iron Chelation and Gallium-Based Therapies for Antibiotic Resistant Bacterial Infections. International Journal of Molecular Sciences, 2021, 22, 2876.	4.1	32
27	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graftâ€versusâ€host disease prophylaxis. EJHaem, 2021, 2, 236-248.	1.0	4
28	Bacterial metabolites trimethylamine N-oxide and butyrate as surrogates of small intestinal bacterial overgrowth in patients with a recent decompensated heart failure. Scientific Reports, 2021, 11, 6110.	3.3	11
29	Evaluation of a rapid antigen test (Panbioâ,,¢ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. Clinical Microbiology and Infection, 2021, 27, 636.e1-636.e4.	6.0	120
30	Performance of a MALDI-TOF mass spectrometry-based method for rapid detection of third-generation oxymino-cephalosporin-resistant Escherichia coli and Klebsiella spp. from blood cultures. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1925-1932.	2.9	7
31	Realâ€life evaluation of a rapid extractionâ€free SARSâ€CoVâ€2 RTâ€PCR assay (COVIDâ€19 PCR Fastâ€L) for th diagnosis of COVIDâ€19. Journal of Medical Virology, 2021, 93, 5233-5235.	^e 5.0	3
32	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graftâ€versusâ€host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transplant Infectious Disease, 2021, 23, e13627.	1.7	5
33	Inhibition of LpxC Increases the Activity of Iron Chelators and Gallium Nitrate in Multidrug-Resistant Acinetobacter baumannii. Antibiotics, 2021, 10, 609.	3.7	4
34	Point-of-care evaluation of a rapid antigen test (CLINITESTⓇ Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals. Journal of Infection, 2021, 82, e11-e12.	3.3	35
35	B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents. Clinical Microbiology and Infection, 2021, 27, 1672-1677.	6.0	26
36	T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19. American Journal of Transplantation, 2021, 21, 2785-2794.	4.7	17

#	Article	IF	CITATIONS
37	Evaluation of a rapid antigen detection test (Panbioâ,,¢ COVIDâ€19 Ag Rapid Test Device) as a pointâ€ofâ€care diagnostic tool for COVIDâ€19 in a pediatric emergency department. Journal of Medical Virology, 2021, 93, 6803-6807.	5.0	24
38	Early detection of SARS-CoV-2 infection cases or outbreaks at nursing homes by targeted wastewater tracking. Clinical Microbiology and Infection, 2021, 27, 1061-1063.	6.0	49
39	Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults. Clinical Microbiology and Infection, 2021, 27, 1858.e1-1858.e7.	6.0	20
40	Cytomegalovirusâ€specific Tâ€cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. British Journal of Haematology, 2021, 195, 637-641.	2.5	4
41	COVID-19 infodemics: the role of mainstream and social media. Clinical Microbiology and Infection, 2021, 27, 1568-1569.	6.0	9
42	Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients. Journal of Clinical Virology, 2021, 142, 104943.	3.1	9
43	Initial viral load and decay kinetics of SARS-CoV-2 lineage B.1.1.7 in the upper respiratory tract of adults and children. Journal of Infection, 2021, 83, 496-522.	3.3	6
44	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. Bone Marrow Transplantation, 2020, 55, 431-440.	2.4	13
45	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. Medical Microbiology and Immunology, 2020, 209, 15-21.	4.8	8
46	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with postâ€ŧransplantation cyclophosphamide. Transplant Infectious Disease, 2020, 22, e13206.	1.7	13
47	Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens. Journal of Infection, 2020, 80, 578-606.	3.3	2
48	Early kinetics of Torque Teno virus DNA load and BK polyomavirus viremia after kidney transplantation. Transplant Infectious Disease, 2020, 22, e13240.	1.7	16
49	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. Journal of Clinical Virology, 2020, 131, 104611.	3.1	61
50	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2020, 23, e13507.	1.7	7
51	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graftâ€versusâ€host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. Transplant Infectious Disease, 2020, 22, e13440.	1.7	4
52	Whole-genome sequencing of Mycobacterium tuberculosis directly from clinical samples for high-resolution genomic epidemiology and drug resistance surveillance: an observational study. Lancet Microbe, The, 2020, 1, e175-e183.	7.3	42
53	Pooling of nasopharyngeal swab specimens for SARS oVâ€2 detection by RTâ€PCR. Journal of Medical Virology, 2020, 92, 2306-2307.	5.0	72
54	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplantation, 2020, 55, 2147-2159.	2.4	24

#	Article	IF	CITATIONS
55	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2020, 22, e13301.	1.7	7
56	Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and Gram staining results. Journal of Infection and Chemotherapy, 2020, 26, 963-969.	1.7	6
57	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplantation, 2020, 55, 1347-1356.	2.4	9
58	A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score. Journal of Infectious Diseases, 2020, 222, 479-487.	4.0	2
59	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. Journal of Infection, 2020, 80, 333-341.	3.3	7
60	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. Biology of Blood and Marrow Transplantation, 2020, 26, 972-977.	2.0	11
61	Field performance of the Abbott RealTime MTB assay for the diagnosis of extrapulmonary tuberculosis in a low-prevalence setting. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 206-211.	0.5	4
62	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplantation, 2020, 55, 1493-1496.	2.4	2
63	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. Bone Marrow Transplantation, 2019, 54, 90-98.	2.4	12
64	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. Transplant Infectious Disease, 2019, 21, e13158.	1.7	17
65	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. American Journal of Transplantation, 2019, 19, 2479-2494.	4.7	45
66	High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. PLoS Medicine, 2019, 16, e1002961.	8.4	62
67	Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infectious Diseases, The, 2019, 19, e260-e272.	9.1	285
68	Cytomegalovirus DNAemia in patients with <i>de novo</i> acute myeloid leukemia undergoing cytotoxic chemotherapy. Leukemia and Lymphoma, 2019, 60, 3081-3083.	1.3	0
69	Adoption of new technologies in laboratory workflow practices for positive blood culture bottles: a cross-sectional survey among hospitals in the Autonomous Community of Valencia, Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1199-1202.	2.9	0
70	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. Medical Microbiology and Immunology, 2019, 208, 405-414.	4.8	3
71	Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. Medical Microbiology and Immunology, 2019, 208, 253-258.	4.8	19
72	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. Journal of Infection, 2019, 78, 393-401.	3.3	17

#	Article	IF	CITATIONS
73	Spontaneouslyâ€resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. Journal of Medical Virology, 2019, 91, 1128-1135.	5.0	3
74	Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients. Therapeutic Drug Monitoring, 2019, 41, 740-747.	2.0	5
75	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. Clinical Infectious Diseases, 2019, 68, 1894-1903.	5.8	36
76	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Journal of Infectious Diseases, 2019, 219, 1510-1512.	4.0	2
77	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. Diagnostic Microbiology and Infectious Disease, 2019, 94, 22-27.	1.8	5
78	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1022-1030.	2.0	11
79	Hydrogen- and Methane-Based Breath Testing and Outcomes in Patients With Heart Failure. Journal of Cardiac Failure, 2019, 25, 319-327.	1.7	14
80	Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation. American Journal of Transplantation, 2019, 19, 1139-1149.	4.7	57
81	Going beyond serology for stratifying the risk of CMV infection in transplant recipients. Reviews in Medical Virology, 2019, 29, e2017.	8.3	22
82	Missing Cases of Herpes Simplex Virus (HSV) Infection of the Central Nervous System When the Reller Criteria Are Applied for HSV PCR Testing: a Multicenter Study. Journal of Clinical Microbiology, 2019, 57, .	3.9	7
83	Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. Haematologica, 2019, 104, 2155-2163.	3.5	82
84	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. Bone Marrow Transplantation, 2018, 53, 787-790.	2.4	5
85	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. Journal of Medical Virology, 2018, 90, 1375-1382.	5.0	3
86	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. American Journal of Transplantation, 2018, 18, 2885-2894.	4.7	22
87	Are pathogenic intestinal bacteria present in stool specimens from patients with chronic heart failure?. Diagnostic Microbiology and Infectious Disease, 2018, 91, 141-143.	1.8	5
88	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. Clinical Infectious Diseases, 2018, 67, 805-807.	5.8	12
89	Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study. Journal of Clinical Microbiology, 2018, 5 <u>6, .</u>	3.9	9
90	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. Biology of Blood and Marrow Transplantation, 2018, 24, 563-570.	2.0	31

#	Article	IF	CITATIONS
91	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) proteomic profiling of cerebrospinal fluid in the diagnosis of enteroviral meningitis: a proof-of-principle study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2331-2339.	2.9	7
92	Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients. Scientific Reports, 2018, 8, 15490.	3.3	59
93	Communityâ€acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virusâ€bacterial mixed infections. Transplant Infectious Disease, 2018, 20, e12926.	1.7	24
94	The Culpability of Respiratory Viruses in Pneumonia-Related Acute Respiratory Failure. Chest, 2018, 154, 223.	0.8	0
95	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2018, 90, 1438-1443.	5.0	15
96	A survey on practices for active surveillance of carriage of multidrug-resistant bacteria in hospitals in the Autonomous Community of Valencia, Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2069-2074.	2.9	5
97	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients. Journal of Medical Microbiology, 2018, 67, 814-819.	1.8	2
98	Impact of cytomegalovirus <scp>DNA</scp> emia on overall and nonâ€relapse mortality in allogeneic stem cell transplant recipients. Transplant Infectious Disease, 2017, 19, e12717.	1.7	18
99	Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. Annals of Hematology, 2017, 96, 1253-1270.	1.8	18
100	A riskâ€adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. Transplant Infectious Disease, 2017, 19, e12729.	1.7	17
101	Comparison of the artus Epstein–Barr virus (EBV) PCR kit and the Abbott RealTime EBV assay for measuring plasma EBV DNA loads in allogeneic stem cell transplant recipients. Diagnostic Microbiology and Infectious Disease, 2017, 88, 36-38.	1.8	12
102	Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An <scp>ESGICH</scp> survey. Transplant Infectious Disease, 2017, 19, e12773.	1.7	26
103	The molecular epidemiology of HIV-1 in the Comunidad Valenciana (Spain): analysis of transmission clusters. Scientific Reports, 2017, 7, 11584.	3.3	29
104	Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. Journal of Clinical Virology, 2017, 94, 22-28.	3.1	44
105	Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?. Journal of Clinical Virology, 2017, 97, 26-32.	3.1	9
106	IL28B genetic variation and cytomegalovirusâ€specific Tâ€cell immunity in allogeneic stem cell transplant recipients. Journal of Medical Virology, 2017, 89, 685-695.	5.0	10
107	Assessing the risk of cytomegalovirus DNAaemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma. Journal of General Virology, 2017, 98, 1855-1863.	2.9	2
108	The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. Journal of General Virology, 2017, 98, 2530-2542.	2.9	10

#	Article	IF	CITATIONS
109	Short-term incubation of positive blood cultures in brain-heart infusion broth accelerates identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry. Journal of Medical Microbiology, 2017, 66, 1752-1758.	1.8	15
110	Identification of a large, fast-expanding HIV-1 subtype B transmission cluster among MSM in Valencia, Spain. PLoS ONE, 2017, 12, e0171062.	2.5	13
111	Expanding role of cytomegalovirus as a human pathogen. Journal of Medical Virology, 2016, 88, 1103-1112.	5.0	31
112	Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. Transplant International, 2016, 29, 1196-1204.	1.6	4
113	Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design. Drug Discovery Today, 2016, 21, 674-681.	6.4	7
114	Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Reviews, 2016, 30, 35-48.	5.7	34
115	Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice. Transplant International, 2015, 28, 1042-1054.	1.6	29
116	Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. Journal of General Virology, 2015, 96, 2822-2831.	2.9	29
117	Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens. Diagnostic Microbiology and Infectious Disease, 2015, 82, 40-43.	1.8	21
118	Expansion of the CRF19_cpx Variant in Spain. Journal of Clinical Virology, 2015, 69, 146-149.	3.1	17
119	Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia. Journal of Medical Virology, 2015, 87, 1601-1607.	5.0	5
120	Intra- and Interinstitutional Evaluation of an Etest for Vancomycin Minimum Inhibitory Concentration Measurement inStaphylococcus aureusBlood Isolates: Figure 1 Clinical Infectious Diseases, 2015, 61, 1490-1492.	5.8	12
121	Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. Journal of Clinical Microbiology, 2015, 53, 2741-2744.	3.9	15
122	Plasma metabolomics profiling for the prediction of cytomegalovirus DNAemia and analysis of virus–host interaction in allogeneic stem cell transplant recipients. Journal of General Virology, 2015, 96, 3373-3381.	2.9	6
123	Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 ⁺ T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2014, 58, 5602-5605.	3.2	24
124	Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy, 2014, 69, 1620-1623.	3.0	34
125	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. Seminars in Thrombosis and Hemostasis, 2013, 39, 973-973.	2.7	1
126	Active Cytomegalovirus Infection in Nonimmunosuppressed Patients in the ICU. Chest, 2011, 140, 269-270.	0.8	2

#	Article	IF	CITATIONS
127	Performance of an automated human immunodeficiency virus (HIV) antigen/antibody combined assay for prenatal screening for HIV infection in pregnant women. Journal of Medical Microbiology, 2009, 58, 1529-1530.	1.8	9
128	Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. Journal of Medical Virology, 2001, 64, 35-41.	5.0	17
129	Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. Journal of Medical Virology, 2001, 65. 77-84.	5.0	16
130	Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV		13

Antibody response to human cytomegau end-organ disease. , 1998, 55, 272-280.